The fetal liver and thymus tissue are implanted as human tissue components, whereas CD34+ hematopoietic stem cells provide the transplanted cell source that engrafts. Once established, these stem cells produce multiple human immune cell types. Considering both tissue implantation and stem-cell engraftment helps investigators examine human immune development within a living host.
Engraftment marks the establishment of transplanted human CD34+ cells in the mouse and their production of multiple human immune cell types. This process gives the model a human hematopoietic component, not merely implanted human tissue. As a result, investigators can examine human immune development and immune-related processes in vivo, where those cells operate within a living organism.
The key distinction is the presence of human immune components generated through human tissue implantation and CD34+ stem-cell engraftment. Conventional laboratory mice can therefore produce immune findings that do not fully match human responses, whereas BLT models are designed to reveal where human and mouse immune behavior differs. This comparison is valuable when interpreting medical disease or therapy results.
The workflow consists of implanting human fetal liver and thymus tissue under the mouse kidney capsule, followed by transplantation of human CD34+ hematopoietic stem cells. After engraftment, the mice produce multiple human immune cell types. This sequence establishes the humanized in vivo setting used for studies of immune development, infection, cancer, transplantation, and immune-mediated disease.
Because the model contains multiple human immune cell types in vivo, it can be used to examine host-pathogen interactions in a setting that includes human immune components. Researchers can investigate how pathogens encounter and affect those cells, then compare observations with responses from conventional mice. This makes the model relevant to medical studies focused on infection biology and human-specific immune behavior.
BLT models support investigations of cancer, transplantation, and immune-mediated disease, in addition to infection research. Their human immune components allow experimental therapies and disease-related immune responses to be examined in a living system. Findings can also highlight differences between human and conventional mouse immunity, helping researchers interpret how well experimental results may reflect human biology.